Recently, Mansouri et al. (2015) and Skendros et al. (2017) independently showed that using IL-1β antagonists, such as canakinumab and gevokizumab, can successfully reduce the area and severity index scores of generalized pustular psoriasis. Here, IL1B is linked to generalized pustular psoriasis.